The role of nebulised budesonide in the treatment of exacerbations of COPD

@article{Gunen2007TheRO,
  title={The role of nebulised budesonide in the treatment of exacerbations of COPD},
  author={Hakan Gunen and Suleyman Savas Hacievliyagil and Ozkan Yetkin and Gazi Gulbas and Levent Cem Mutlu and Erdal İn},
  journal={European Respiratory Journal},
  year={2007},
  volume={29},
  pages={660 - 667}
}
The present study was designed to evaluate the hypothesis that nebulised budesonide (NB) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (ECOPD). Patients hospitalised with ECOPD (n = 159) were randomised into three groups. Group 1 received only standard bronchodilator treatment (SBDT), group 2 received SC (40 mg prednisolone) plus SBDT, and group 3 received NB (1,500 μg q.i.d.) plus SBDT… 
View on ERS
erj.ersjournals.com
86 Citations
Highly Influential Citations
4
Background Citations
29
Methods Citations
3
Results Citations
6

86 Citations

Citation Type

Citation Type

Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
TLDR
Compared to the conventional dose (4 mg/day), a high dose of NB improved pulmonary function and symptoms more effectively in the early treatment of AECOPD, especially when given as 4 mg twice daily.
CLINICAL EFFICACY OF NEBULIZED BUDESONIDE IN ACUTE EXACERBATION OF COPD
TLDR
Nebulised budesonide was equally as efficacious as parental steroids in AECOPD and showed better improvement in SGRQ score as compared to control group.
Effectivness of Nebulized Budesonide for COPD Exacerbation Management in Emergency Department; a Randomized Clinical Trial
TLDR
NB, compared to OP, could more effectively increase PEFR and ameliorate disease severity of patients with COPD exacerbation at 12 and 24 hours after treatment in ED.
Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: A randomized control trial
  • E. Uçar, O. Araz, +5 authors M. Akgun
  • Medicine
    Medical science monitor : international medical journal of experimental and clinical research
  • 2014
TLDR
Nebulized budesonide may be used as an alternative to SC because of its equal effectiveness and lesser systemic adverse effects and the choice of optimal dosage needs to be evaluated carefully because adverse effect and dropout rates varied according to dosage.
CLINICAL EVALUATION OF NEBULISED BUDESONIDE IN ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE– A RANDOMISED STUDY
[Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: Efficacy, safety, and effects on the serum levels of soluble differentiation molecules].
TLDR
Nebulized budesonide is an effective and safe alternative to SGCS in treating an exacerbation of COPD and causes a decrease in the serum level of soluble interleukin-2 receptor (sCD25) in both groups.
Clinical Outcomes Of Using Nebulized Budesonide As The Initial Treatment For Acute Exacerbations Of Chronic Obstructive Pulmonary Disease: A Post-Hoc Analysis
TLDR
Results indicate that NBS may be used as an initial treatment in certain AECOPD patients, and further studies are needed to better define those most likely to benefit.
COPD_A_235125 409..415
TLDR
Compared to the conventional dose, a high dose of nebulized budesonide improved pulmonary function and symptoms more effectively in the early treatment of AECOPD, especially when given as 4 mg twice daily.
Assessment of high-dose inhalational corticosteroids vs systemic corticosteroids in acute exacerbations of COPD in diabetic patients
TLDR
Both ICS and SCS improve airflow in patients with A ECOPD, taking into consideration the existence of diabetes mellitus, and ICS may be an excellent substitute to SCS in the treatment of AECOPD in diabetic patients.
The role of nebulised budesonide in the treatment of acute exacerbations of COPD
From the authors : We have read with interest the letter concerning our manuscript recently published in the European Respiratory Journal 1 and appreciate the concerns raised by A. Singh.…
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Comparison of the Efficacy of Nebulised Budesonide with Parenteral Corticosteroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
TLDR
It is suggested that nebulised budesonide may be an alternative to parenteral corticosteroids in the treatment of acute exacerbations of COPD.
A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease
Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma.
TLDR
It is demonstrated that nebulized FP is at least as effective as oral prednisolone in the treatment of children presenting with an acute exacerbation of asthma.
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation.
TLDR
Outpatient treatment of acute COPD exacerbation with prednisone accelerates recovery of PaO2, A-aDO2, FEV1, and PEF, reduces the treatment failure rate, and improves subjective dyspnea.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial
Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma.
Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.
TLDR
Outpatient treatment with oral prednisone offers a small advantage over placebo in treating patients who are discharged from the emergency department with an exacerbation of COPD.
Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care.
TLDR
There is no evidence of a significant difference in efficacy between a reducing dose course of oral prednisolone and high dose inhaled fluticasone propionate in mild exacerbations of asthma which do not require admission to hospital.
Corticosteroids contribute to muscle weakness in chronic airflow obstruction.
TLDR
In patients with COPD or asthma, respiratory and peripheral muscle strength and steroid treatment are interrelated despite the relatively low doses administered, demonstrating further limitations on the prolonged treatment of chronic airflow obstruction with systemic corticosteroids.
Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD.
TLDR
Hospitalized patients with ECOPDs experience significant changes in systemic cytokine levels that correlate with symptoms and lung function.
...
1
2
3
4
...